From monoclonal antibodies (mAbs) that treat ailments such as cancer and arthritis to messenger RNA (mRNA) vaccines to fight a pandemic, biopharma’s place in global healthcare has rarely been more prominent. By 2030 the global market for biopharmaceuticals is projected to reach $856.1 billion and expand at a compound annual growth rate (CAGR) of 12.5% from 2021 to 2030. In response to the increasing number of infectious diseases around the world antibody development is also fuelling tremendous growth in the biopharmaceutical manufacturing sector. Hans J. Johansson at Purolite Life Sciences looks over supply chain resilience for bioprocess resins and future-proofing downstream bioprocessing.